Replies to post #5217 on Arbutus Biopharma Corporation (ABUS)

[DewDiligence]

I am curious what theories we have about why the sudden spike in volume, seemingly on no news since the disappointing trial results about a month ago.

The impetus was Roche’s deal with DRNA announced yesterday to develop RNAi drugs for HBV (#msg-152014949).

I'm not especially bullish on ABUS, but I'm following it because I'm long ENTA, who has an HBV program that will soon start phase-1. Regards, Dew

p.s. Welcome back to iHub!